Treatment Sequencing in HR+ mBC

 

Dana-Farber Cancer Institute
S

ASCO® 2023 Insights: "TROPiCS-02 Final OS Analysis of Sacituzumab Govitecan in Pts With HR+/HER2- mBC"

By Dana-Farber Cancer Institute FEATURING Sara Tolaney
By Dana-Farber Cancer Institute FEATURING Sara Tolaney
166 views
June 14, 2023
0 Comments
Login to view comments. Click here to Login
Treatment Sequencing in HR+ mBC
18:52
PrecisCa

Expert Case Discussion: 68 y/o With HR+/HER2- mBC With Progression t…

Feat. R. L. Mahtani, W. Gradishar, J. O'Shaughnessy
04:37
Christine Brezden-Masley

ADCs in ER+/HER2- mBC

24:23
OncoAlert

ADCs for BC: Current Clinical Evidence

Feat. H. Rugo
01:46
Dana-Farber Cancer Institute

ASCO® 2023 Insights: "TROPiCS-02 Final OS Analysis of Sacituzum…

Feat. S. Tolaney
11:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino
23:58
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "mBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri
08:00
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary Efficacy Analyses of NeoRHEA, Neo…

Feat. M. Ignatiadis
09:32
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysi…

Feat. S. Tolaney
12:48
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Association of Tumor-Infiltrating Lymphoc…

Feat. M. Tesch